According to a new report Global Heparin Market, published by KBV research, The Global Heparin Market size is expected to reach $10 billion by 2027, rising at a market growth of 6.5% CAGR during the forecast period.
On the basis of product, the low molecular weight heparin segment procured the highest revenue share of the global heparin market. It would exhibit similar trend even during the forecast period. The low molecular weight heparin has longer and more predictable operation as compared to UFH. It can be self-administered at home by subcutaneous injection, thus decreases or eliminates the duration of hospital stays.
Coronary artery disease procured the largest share in 2020 due to the increasing incidence of heart-related disorders. According to the American Heart Association, data published in 2018, there are about 92.1 million American adults who were affected by some kind of cardiovascular disease. Moreover, 1 in every 3 deaths is occurred due to cardiovascular disease in the U.S., and this accounted for approximately 2,300 deaths per day.
The North America market dominated the Global Heparin Market by Region in 2020. Asia-Pacific would be the fastest-growing region during the forecast period. This is due to expanding healthcare infrastructure and the presence of untapped resources in this region. The rapid economic development and initiatives undertaken by private & public organizations are likely to boost the growth of the heparin market in developing countries in Asia-Pacific. Moreover, the larger patient pool for cardiovascular diseases as well as the increasing aging population is a major factor which is driving the growth of the market.
Full Report: https://www.kbvresearch.com/heparin-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Baxter International, Inc., B. Braun Melsungen AG, Fresenius SE & Co. KGaA, Pfizer, Inc., Sanofi S.A., Teva Pharmaceuticals Industries Ltd., Hebei Changshan Biochemical Pharmaceutical Co., Ltd., Dr. Reddy’s Laboratories Ltd., LEO Pharma A/S, and Viatris, Inc.
By Usability
By Product
By Risk Type
By Geography
Companies Profiled
Unique Offerings 
